Overview
Disorders of plasmalogen biosynthesis, also known as plasmalogen deficiency or plasmalogen synthesis defects, are a group of rare inherited metabolic conditions in which the body cannot properly produce plasmalogens — a specialized class of ether phospholipids that are critical components of cell membranes, particularly abundant in the brain, heart, lungs, and kidneys. Plasmalogens play important roles in membrane structure, antioxidant defense, and cellular signaling. The most well-characterized disorders of plasmalogen biosynthesis are the rhizomelic chondrodysplasia punctata (RCDP) spectrum, caused by defects in peroxisomal enzymes involved in the plasmalogen synthesis pathway, including GNPAT (dihydroxyacetone phosphate acyltransferase), AGPS (alkyldihydroxyacetone phosphate synthase), and PEX7 (peroxisomal biogenesis factor 7). Clinical features typically manifest at birth or in early infancy and may include severe skeletal abnormalities such as rhizomelic (proximal) limb shortening, stippled calcifications of cartilage (chondrodysplasia punctata), cataracts, profound intellectual disability, growth failure, seizures, and ichthyosis (dry, scaly skin). The severity of the condition varies depending on the specific genetic defect and the degree of residual plasmalogen synthesis. Many affected individuals have a significantly shortened lifespan, with severe forms often leading to death in infancy or early childhood, though milder phenotypes with longer survival have been described. Currently, there is no curative treatment for disorders of plasmalogen biosynthesis. Management is supportive and multidisciplinary, focusing on nutritional support, physical therapy, orthopedic interventions for skeletal complications, ophthalmologic care for cataracts, and seizure management. Research into plasmalogen replacement therapy and other experimental approaches is ongoing but remains in early stages. Genetic counseling is recommended for affected families.
Autosomal recessive
Passed on when both parents carry the same gene change; often skips generations
Neonatal
Begins at or shortly after birth (first 4 weeks)
Treatments
No FDA-approved treatments are currently listed for Disorder of plasmalogens biosynthesis.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Disorder of plasmalogens biosynthesis at this time.
New trials open frequently. Follow this disease to get notified.
Specialists
View all specialists →No specialists are currently listed for Disorder of plasmalogens biosynthesis.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Disorder of plasmalogens biosynthesis.
Community
No community posts yet. Be the first to share your experience with Disorder of plasmalogens biosynthesis.
Start the conversation →Latest news about Disorder of plasmalogens biosynthesis
No recent news articles for Disorder of plasmalogens biosynthesis.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Disorder of plasmalogens biosynthesis
What is Disorder of plasmalogens biosynthesis?
Disorders of plasmalogen biosynthesis, also known as plasmalogen deficiency or plasmalogen synthesis defects, are a group of rare inherited metabolic conditions in which the body cannot properly produce plasmalogens — a specialized class of ether phospholipids that are critical components of cell membranes, particularly abundant in the brain, heart, lungs, and kidneys. Plasmalogens play important roles in membrane structure, antioxidant defense, and cellular signaling. The most well-characterized disorders of plasmalogen biosynthesis are the rhizomelic chondrodysplasia punctata (RCDP) spectrum
How is Disorder of plasmalogens biosynthesis inherited?
Disorder of plasmalogens biosynthesis follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does Disorder of plasmalogens biosynthesis typically begin?
Typical onset of Disorder of plasmalogens biosynthesis is neonatal. Age of onset can vary across affected individuals.